Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Finishing Mixed This Afternoon

11/22/2021 | 04:06pm EST


ę MT Newswires 2021
All news about BIOCRYST PHARMACEUTICALS, INC.
01/13INSIDER SELL : Biocryst Pharmaceuticals
MT
01/11BioCryst Announces Preliminary Full Year 2021 ORLADEYO (berotralstat) Net Revenue and P..
AQ
01/10Health Care Stocks Return to Positive Ground This Afternoon
MT
01/10Health Care Stocks Edging Lower in Monday Afternoon Trading
MT
01/10BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral..
AQ
01/10BioCryst Pharmaceuticals Preliminary Net Revenue for Orladeyo in Q4, Full Year
MT
01/10BIOCRYST PHARMACEUTICALS : —ORLADEYO net revenue expected to more than double in 202..
PU
01/10BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation F..
AQ
01/10BioCryst Announces Preliminary Full Year 2021 ORLADEYO« (berotralstat) Net Revenue and ..
AQ
01/10BioCryst Pharmaceuticals, Inc. Provides ORLADEYO Net Revenue and Peak Sales Guidance fo..
CI
More news
Analyst Recommendations on BIOCRYST PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 157 M - -
Net income 2021 -225 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,4x
Yield 2021 -
Capitalization 2 785 M 2 785 M -
Capi. / Sales 2021 17,8x
Capi. / Sales 2022 11,2x
Nbr of Employees 246
Free-Float -
Chart BIOCRYST PHARMACEUTICALS, INC.
Duration : Period :
BioCryst Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCRYST PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 15,48 $
Average target price 19,92 $
Spread / Average Target 28,7%
EPS Revisions
Managers and Directors
Jon P. Stonehouse President, Chief Executive Officer & Director
Michael L. Jones Executive Director-Finance
Anthony Doyle Chief Financial Officer, Treasurer & Senior VP
Robert Alexander Ingram Chairman
William P. Sheridan Chief Medical Officer & Senior Vice President
Sector and Competitors